Brief for Amicus Curiae Eric S. Lander in Support of Neither Party by Lander, Eric
No. 12-398 
================================================================ 
In The 
Supreme Court of the United States 
--------------------------------- i --------------------------------- 
THE ASSOCIATION FOR  
MOLECULAR PATHOLOGY, ET AL., 
Petitioners,        
v. 
MYRIAD GENETICS, INC., ET AL., 
Respondents.        
--------------------------------- i --------------------------------- 
On Writ of Certiorari to the  
United States Court of Appeals 
for the Federal Circuit 
--------------------------------- i --------------------------------- 
BRIEF FOR AMICUS CURIAE ERIC S. LANDER  
IN SUPPORT OF NEITHER PARTY 
--------------------------------- i --------------------------------- 
GIDEON A. SCHOR 
 Counsel of Record 
VERN NORVIEL 
WILSON SONSINI GOODRICH & ROSATI 
PROFESSIONAL CORPORATION 
1301 Avenue of the Americas,  
 40th Floor 
New York, NY 10019 
(212) 999-5800 
gschor@wsgr.com 
I. GLENN COHEN 
ASSISTANT PROFESSOR 
CO-DIRECTOR,  
 PETRIE-FLOM CENTER FOR  
 HEALTH LAW POLICY, 
 BIOTECHNOLOGY, AND BIOETHICS 
HARVARD LAW SCHOOL 
Griswold Hall, Room 523 
1525 Massachusetts Avenue 
Cambridge, MA 02138 
(617) 496-2518 
igcohen@law.harvard.edu 
Attorneys for Amicus Curiae 
 Eric S. Lander 
================================================================ 
COCKLE LAW BRIEF PRINTING CO. (800) 225-6964 
OR CALL COLLECT (402) 342-2831 
i 
 
TABLE OF CONTENTS 
Page 
STATEMENT OF INTEREST OF AMICUS 
CURIAE ............................................................ 1 
SUMMARY OF THE ARGUMENT ...................... 2 
ARGUMENT ........................................................ 5 
 I.   THE FEDERAL CIRCUIT INCORRECT-
LY ASSUMED, WITHOUT CITING SCI-
ENTIFIC EVIDENCE, THAT ISOLATED 
DNA FRAGMENTS OF THE HUMAN 
GENOME DO NOT OCCUR IN NA-
TURE, WHEN IT IS WELL-ACCEPTED 
IN THE SCIENTIFIC COMMUNITY 
THAT THEY DO ........................................ 6 
A.   Myriad’s patents cover isolated DNA 
fragments from the human genome .... 7 
B.   The Federal Circuit assumed, with-
out citing scientific evidence, that iso-
lated DNA fragments of the human 
genome do not occur in Nature and 
therefore inappropriately used rea-
soning-by-analogy to decide whether 
such fragments are “similar” to or 
“markedly different” from products of 
Nature ................................................. 10 
C.   It is well-accepted in the scientific 
community that isolated DNA frag-
ments of the human genome – includ-
ing many fragments covered by 
Myriad’s patents – occur routinely in 
the human body and thus are prod-
ucts of Nature ...................................... 12 
ii 
 
TABLE OF CONTENTS – Continued 
Page 
 II.   MYRIAD’S COMPOSITION-OF-MATTER 
CLAIMS ON ISOLATED FRAGMENTS 
OF GENOMIC DNA ARE INCON-
SISTENT WITH THIS COURT’S SEC-
TION 101 JURISPRUDENCE BECAUSE 
THEY (1) ARE DIRECTED TO PRE-
EXISTING PRODUCTS OF NATURE; (2) 
EXCLUDE OTHERS FROM OBSERV-
ING, CHARACTERIZING OR ANALYZ-
ING THESE PRODUCTS OF NATURE 
BY ANY MEANS WHATSOEVER; AND 
(3) CREATE AN INSURMOUNTABLE 
BARRIER TO SCIENTIFIC PROGRESS 
AND TECHNOLOGICAL INNOVATION 
CONCERNING THESE PRODUCTS OF 
NATURE .................................................... 18 
A.   Composition-of-matter claims on 
products of Nature, such as Myriad’s 
claims on naturally occurring DNA 
fragments of the human genome, are 
inconsistent with this Court’s Section 
101 Jurisprudence. .............................. 18 
B.   The rationale for barring patents on a 
product of Nature is strongest when a 
patent would wall off an entire do-
main of Nature from study and inno-
vation ................................................... 22 
  
iii 
 
TABLE OF CONTENTS – Continued 
Page 
C.   Myriad’s composition-of-matter claims 
on genomic DNA are directed to pre-
existing products of Nature; exclude 
others from observing, characterizing 
or analyzing these products of Nature 
by any means whatsoever; and create 
an insurmountable barrier to scien-
tific innovation on these products of 
Nature with serious consequences for 
medical progress and technological 
innovation ............................................ 25 
 III.   A NARROWLY CRAFTED DECISION BY 
THIS COURT WOULD NOT UNDER-
MINE THE BIOTECHNOLOGY INDUS-
TRY AND INSTEAD WOULD FOSTER 
INNOVATION ............................................ 26 
A.   Most medically and commercially im-
portant biotechnology products de-
pend on patent protection for non-
naturally occurring DNA molecules, 
such as cDNAs and recombinant 
DNAs, rather than on products of 
Nature such as fragments of genomic 
DNA ..................................................... 27 
B.   The unfettered ability to observe, 
characterize and analyze the human 
genome will foster scientific progress 
and technological innovation .............. 28 
CONCLUSION ..................................................... 29 
 
iv 
 
TABLE OF AUTHORITIES 
Page 
CASES 
Association for Molecular Pathology v. United 
States Patent & Trademark Office, 689 F.3d 
1303 (Fed. Cir.), cert. granted sub nom. Asso-
ciation for Molecular Pathology v. Myriad 
Genetics, Inc., 133 S. Ct. 694 (2012) ....... 7-12, 21, 26 
Diamond v. Chakrabarty, 447 U.S. 303 
(1980) ........................................... 2, 10, 11, 19, 20, 21 
Diamond v. Diehr, 450 U.S. 175 (1981) ............... 19, 22 
Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 
U.S. 127 (1948) .............................................. 4, 19, 29 
Gottschalk v. Benson, 409 U.S. 63 (1972) ........ 4, 22, 24 
Hartranft v. Wiegmann, 121 U.S. 609 (1887) ............ 19 
Mayo Collaborative Servs. v. Prometheus Labs, 
132 S. Ct. 1289 (2012) ........................... 19, 20, 22, 23 
 
STATUTES 
35 U.S.C. § 101 ....................................... 2, 4, 18, 19, 21 
 
MISCELLANEOUS 
Diana W. Bianchi et al., Fetal Genes in Moth-
er’s Blood, 487 Nature 304 (2012) .......................... 16 
Kevin A. Boynton et al., DNA Integrity as a 
Potential Marker for Stool-based Detection of 
Colorectal Cancer, 49 Clin. Chem. 1058 
(2003) ....................................................................... 17 
v 
 
TABLE OF AUTHORITIES – Continued 
Page 
Alison M. Dunning et al., Common BRCA1 
Variants and Susceptibility to Breast and 
Ovarian Cancer in the General Population, 6 
Hum. Mol. Genet. 285 (1997) ................................. 26 
Francine Durocher et al., Comparison of 
BRCA1 Polymorphisms, Rare Sequence Vari-
ants and/or Missense Mutations in Unaffect-
ed and Breast/Ovarian Cancer Populations, 5 
Hum. Mol. Genet. 835 (1996) ................................. 26 
H. Christina Fan et al., Analysis of the Size 
Distributions of Fetal and Maternal Cell-Free 
DNA by Paired-End Sequencing, 56 Clin. 
Chem. 1279 (2010) ............................................ 14, 15 
H. Christina Fan et al., Non-invasive Prenatal 
Measurement of the Fetal Genome, 487 Na-
ture 320 (2012) ........................................................ 16 
H. Christina Fan et al., Noninvasive Diagnosis 
of Fetal Aneuploidy by Shotgun Sequencing 
DNA from Maternal Blood, 105 Proc. Natl. 
Acad. Sci. 16266 (2008) ........................................... 15 
Ioannis Fatouros et al., Cell-Free Plasma DNA 
as a Novel Marker of Aseptic Inflammation 
Severity Related to Exercise Overtraining, 52 
Clin. Chem. 1820 (2006) ......................................... 14 
Mary Beth Giacona et al., Cell-Free DNA in 
Human Blood Plasma: Length Measurements 
in Patients with Pancreatic Cancer and 
Healthy Controls, 17 Pancreas 89 (1998) ............... 15 
vi 
 
TABLE OF AUTHORITIES – Continued 
Page 
Tran Thi Ngoc Ha et al., Elevated Levels of 
Cell-Free Circulating DNA in Patients with 
Acute Dengue Virus Infection, 6 PLoS1 
e25969 (2011) .......................................................... 14 
Jacob O. Kitzman et al., Noninvasive Whole-
Genome Sequencing of a Human Fetus, 4 Sci. 
Transl. Med. 137ra76 (2012) ................................... 16 
Nicole Y.L. Lam et al., Time Course of Early 
and Late Changes in Plasma DNA in Trau-
ma Patients, 49 Clin. Chem. 1286 (2003) ............... 14 
Eric S. Lander et al., Initial Sequencing and 
Analysis of the Human Genome, 409 Nature 
860 (2001) ............................................................ 6, 28 
Eric S. Lander, Initial Impact of the Sequenc-
ing of the Human Genome, 470 Nature 187 
(2011) ....................................................................... 28 
Richard M. Lawn et al., The Isolation and 
Characterization of Linked Delta- and Beta-
globin Genes from a Cloned Library of Hu-
man DNA, 15 Cell 1557 (1978)  ................................ 8 
Xuesong Liu et al., The 40-kDa Subunit of 
DNA Fragmentation Factor Induces DNA 
Fragmentation and Chromatin Condensation 
During Apoptosis, 95 Proc. Natl. Acad. Sci. 
8461 (1998) .............................................................. 13 
Y.M. Dennis Lo et al., Maternal Plasma DNA 
Sequencing Reveals the Genome-Wide Genet-
ics and Mutational Profile of the Fetus, 2 Sci. 
Transl. Med. 61ra91 (2010) ..................................... 16 
vii 
 
TABLE OF AUTHORITIES – Continued 
Page 
Tom Maniatis et al., The Isolation of Structural 
Genes from Libraries of Eucaryotic DNA, 15 
Cell 687 (1978) .......................................................... 8 
Florent Mouliere et al., High Fragmentation 
Characterizes Tumour-Derived Circulating 
DNA, 6 PLoS1 e23418 (2011) ................................. 15 
Thierry Nouspikel et al., Mutations That 
Disable the DNA Repair Gene XPG in a 
Xeroderma Pigmentosum Group G Patient, 3 
Hum. Mol. Genet. 963 (1994) ................................. 14 
Timothy H. Rainer et al., Prognostic Use of 
Circulating Plasma Nucleic Acid Concentra-
tions in Patients with Acute Stroke, 49 Clin. 
Chem. 562 (2003) .................................................... 14 
Andrew G. Renehan et al., What is Apoptosis, 
and Why Is It Important?, 322 Br. Med. J. 
1536 (2001) .............................................................. 12 
Hyoung Doo Shin et al., Common DNase I 
Polymorphism Associated with Autoantibody 
Production Among Systemic Lupus 
Erythematosus Patients, 13 Hum. Mol. 
Genet. 2343 (2004) .................................................. 13 
Anneke M. Sijbers et al., Xeroderma 
Pigmentosum Group F Caused by a Defect in 
a Structure-Specific DNA Repair Endonucle-
ase, 86 Cell 811 (1996) ...................................... 13-14 
  
viii 
 
TABLE OF AUTHORITIES – Continued 
Page 
Todd M. Smith et al., Complete Genomic Se-
quence and Analysis of 117 kb of Human 
DNA Containing the Gene BRCA1, 6 Gen. 
Res. 1029 (1996) ........................................................ 6 
George D. Sorenson et al., Soluble Normal and 
Mutated DNA Sequences from Single-copy 
Genes in Human Blood, 3 Cancer Epidemiol. 
Biomarkers Prev. 67 (1994) .................................... 15 
Maurice Stroun et al., Isolation and Character-
ization of DNA from the Plasma of Cancer 
Patients, 23 Eur. J. Cancer. Clin. Onc. 707 
(1987) ....................................................................... 14 
Ying-Hsiu Su et al., Human Urine Contains 
Small, 150 to 250 Nucleotide-sized, Soluble 
DNA Derived from the Circulation and May 
Be Useful in the Detection of Colorectal Can-
cer, 6 J. Mol. Diagn. 101 (2004) .............................. 17 
F. B. J. M. Thunnissen et al., Sputum Exami-
nation for Early Detection of Lung Cancer, 56 
J. Clin. Pathol. 805 (2003) ...................................... 17 
Miep A. van der Drift, Circulating DNA Is a 
Non-invasive Prognostic Factor for Survival 
in Non-small Cell Lung Cancer, 68 Lung 
Cancer 283 (2008) ................................................... 17 
Jerry R. Williams et al., Association of Mam-
malian Cell Death with a Specific 
Endonucleolytic Degradation of DNA, 252 
Nature 754 (1974) ................................................... 13 
ix 
 
TABLE OF AUTHORITIES – Continued 
Page 
Annemarie Ziegler et al., Circulating DNA: A 
New Diagnostic Gold Mine?, 28 Cancer 
Treatment Rev. 255 (2002) ...................................... 17 
 
PATENTS 
U.S. Patent No. 5,747,282 (issued May 5, 1998) ......... 7 
U.S. Patent No. 5,837,492 (issued November 
17, 1998) .................................................................... 7 
1 
STATEMENT OF INTEREST  
OF AMICUS CURIAE* 
 Amicus Curiae Eric S. Lander was one of the 
principal leaders of the Human Genome Project 
(HGP), the international project that determined and 
made freely available the DNA sequence of the hu-
man genome. Dr. Lander directed the largest center 
in the HGP, which generated approximately one-third 
of the human genome sequence. 
 Dr. Lander is a geneticist, molecular biologist 
and mathematician. He serves as President and 
Founding Director of the Broad Institute of Harvard 
and MIT, a nonprofit biomedical research institution 
focused on genomic medicine. He is also Professor of 
Biology at the Massachusetts Institute of Technology 
and Professor of Systems Biology at Harvard Medical 
School. In addition, he has been a founder of several 
biotechnology firms.  
 Dr. Lander was elected a member of the U.S. 
National Academy of Sciences in 1997 and a member 
of the U.S. Institute of Medicine in 1999. He has 
received numerous major international awards for his 
research on the human genome. 
 
 * Counsel for all parties have consented to the filing of this 
brief, and their consents have been lodged with the Clerk of this 
Court. No counsel for any party had any role in authoring this 
brief, and no person other than the named amicus and his 
counsel has made any monetary contribution to the preparation 
and submission of this brief. See Rule 37. 
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 Dr. Lander also serves as Co-Chair of the Presi-
dent’s Council of Advisors on Science and Technology 
(PCAST), an advisory group consisting of some of the 
nation’s leading scientists and engineers, who directly 
advise the President and the Executive Office of the 
President. Importantly, however, Dr. Lander wishes 
to emphasize that this brief represents his own 
personal views. The brief is in no way intended as a 
statement of policy or position by the United States 
Government, the Broad Institute, Harvard, MIT, or 
any other entity. 
 In this case, the Federal Circuit held, among 
other things, that claims to isolated DNA fragments 
recite a composition of matter patent-eligible under 
35 U.S.C. § 101. The assumption underlying this 
holding is that such fragments do not occur in Na-
ture. As a leading genomic researcher, Dr. Lander has 
a strong interest in advising the Court that, in fact, 
such fragments routinely occur in Nature and that 
claims to such fragments create an insurmountable 
barrier to scientific innovation.  
--------------------------------- i --------------------------------- 
 
SUMMARY OF THE ARGUMENT 
 This case hinges on a scientific question: whether 
DNA fragments from a human chromosome are (1) 
products of Nature or (2) at least similar enough to 
products of Nature that they should not be considered 
“markedly different.” Diamond v. Chakrabarty, 447 
U.S. 303, 310 (1980). 
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 The members of the Federal Circuit panel below 
agreed that the DNA of a whole human chromosome 
was a product of Nature. But the majority held that 
isolated DNA fragments of a human chromosome 
were not products of Nature. 
 Because the majority made (without citing scien-
tific support) a foundational assumption that isolated 
DNA fragments of the human genome do not them-
selves routinely occur in Nature, it considered whether 
they are similar enough to products of Nature. Em-
ploying analogies, the panel members debated 
whether isolated DNA cleaved from a chromosome 
was akin to a leaf plucked from a tree, or a kidney 
surgically removed from a human body. 
 This reasoning-by-analogy was unnecessary 
because the majority’s foundational assumption is 
demonstrably incorrect: it is well-accepted in the 
scientific community that (a) chromosomes are con-
stantly being broken into DNA fragments by natural 
biological processes that break the covalent bonds 
within DNA chains; (b) these DNA fragments are 
ubiquitous in the human body, both within cells and 
in cell-free blood, urine, sputum and stool; and (c) 
these fragments cover the entire human genome and, 
in particular, include the BRCA1 and BRCA2 genes 
claimed by Myriad’s patents. Myriad’s claims thus 
include DNA fragments that are unambiguously 
products of Nature. 
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 Under this Court’s interpretation of 35 U.S.C. 
§ 101, composition-of-matter patents on such pre-
existing products of Nature are not permissible. Such 
products of Nature are “manifestations of . . . nature, 
free to all men and reserved exclusively to none.” 
Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 
127, 130 (1948). 
 A patent on a product of Nature would authorize 
the patent holder to exclude everyone from observing, 
characterizing or analyzing, by any means whatsoev-
er, the product of Nature. This barrier is inherently 
insurmountable: one cannot study a product of Na-
ture if one cannot legally possess it. A molecule is one 
of the “basic tools” – indeed, the essential tool – for 
studying the molecule itself. Gottschalk v. Benson, 
409 U.S. 63, 67 (1972). A patent on a molecule that is 
a product of Nature would thus authorize a patent 
holder to wall off an entire domain of Nature from 
observation.  
 Finally, the majority held that a decision that 
isolated DNA fragments of the human genome are 
patent-ineligible would disrupt long-settled expecta-
tions and could wreak havoc on the biotechnology 
industry. The majority’s concern is unfounded. 
 Most biotechnology products are protected by 
patents on non-natural DNA molecules, rather than 
naturally occurring genomic DNA. The biotechnology 
industry would not be substantially affected by a 
narrowly crafted decision here holding that (1) frag-
ments of human genomic DNA are patent-ineligible 
5 
where the scientific evidence is clear that the claimed 
molecules themselves are routinely found in Nature 
and where the process for purification or synthesis of 
such molecules is routine but (2) human cDNAs are 
patent-eligible, because these molecules do not occur 
in Nature and have clearly different functional prop-
erties from related products of Nature.  
 On the contrary, such a narrowly crafted decision 
would foster scientific progress and technological 
innovation by guaranteeing an unfettered ability to 
study a remarkable product of Nature – the human 
genome. This ability will lead to countless discoveries 
about human disease, as well as an outpouring of 
medical invention with enormous consequences for 
human health. 
--------------------------------- i --------------------------------- 
 
ARGUMENT 
 This amicus brief provides information and 
perspective concerning several scientific issues at the 
center of the case – namely, whether (1) isolated DNA 
fragments of the human genome are products of 
Nature; (2) patents that foreclose the observation, 
characterization or analysis of products of Nature 
impede scientific progress and technological innova-
tion; and (3) a narrowly crafted decision that isolated 
DNA fragments of the human genome are patent-
ineligible would disrupt the biotechnology industry or 
instead would foster innovation. 
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I. THE FEDERAL CIRCUIT INCORRECTLY 
ASSUMED, WITHOUT CITING SCIEN-
TIFIC EVIDENCE, THAT ISOLATED DNA 
FRAGMENTS OF THE HUMAN GENOME 
DO NOT OCCUR IN NATURE, WHEN IT IS 
WELL-ACCEPTED IN THE SCIENTIFIC 
COMMUNITY THAT THEY DO. 
 The human genome consists of 23 pairs of chro-
mosomes, which together specify the instructions for 
life and harbor variations that can predispose to 
disease. Each chromosome contains a long DNA 
double helix, totaling approximately 3 billion nucleo-
tides in length. The term “gene” typically refers to a 
nucleotide sequence, within a chromosome, that 
encodes instructions for proteins.1  
   
 
 1 Myriad’s patents concern the BRCA1 and BRCA2 genes. 
The BRCA1 gene, for example, consists of a region of ~81,000 
nucleotides on Chromosome 17, which is 88 million nucleotides 
long. Todd M. Smith et al., Complete Genomic Sequence and 
Analysis of 117 kb of Human DNA Containing the Gene BRCA1, 
6 Gen. Res. 1029 (1996); Eric S. Lander et al., Initial Sequencing 
and Analysis of the Human Genome, 409 Nature 860 (2001). The 
BRCA1 gene is transcribed into an initial RNA molecule, which 
is then spliced to yield a shorter mature RNA molecule and 
translated into the BRCA1 protein. Certain variations in the 
DNA sequence of the BRCA1 gene (“spelling differences”) 
predispose women carrying them to develop early-onset breast 
cancer. The BRCA2 gene is on chromosome 13. 
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A. Myriad’s patents cover isolated DNA 
fragments from the human genome. 
 Myriad’s claims on the BRCA1 gene create a 
monopoly on any “isolated DNA” containing “at least” 
15 consecutive bases from any DNA sequence that 
encodes a BRCA1 protein2,3 – including from the 
human BRCA1 gene itself. 
 In the context of Myriad’s patents, “isolated 
DNA” refers to “a free-standing portion of a larger, 
natural DNA molecule. Isolated DNA has been 
cleaved (i.e., had covalent bonds in its backbone 
chemically severed) or synthesized to consist of just a 
fraction of a naturally occurring DNA molecule.” 
Association for Molecular Pathology v. United States 
Patent & Trademark Office, 689 F.3d 1303, 1328 (Fed. 
Cir.), cert. granted sub nom. Association for Molecular 
Pathology v. Myriad Genetics, Inc., 133 S. Ct. 694 
(2012). Isolated DNA has the identical nucleotide 
sequence as in the larger whole; it differs only in 
having been cleaved from the whole.  
 
 2 Claim 5 of the main patent at issue states: “5. An isolated 
DNA having at least 15 nucleotides of the DNA of claim 1.” U.S. 
Patent No. 5,747,282 (issued May 5, 1998) (“ ’282 patent”) col. 
153 ll.66-67. Claim 1, in turn, describes the DNA of the full 
BRCA1 gene: “1. An isolated DNA coding for a BRCA1 polypep-
tide, said polypeptide having the amino acid sequence set forth 
in SEQ ID NO:2.” ’282 patent col. 153 ll.57-59. 
 3 We focus our arguments on claims regarding BRCA1. 
However, they apply mutatis mutandis to the analogous claims 
regarding BRCA2 in U.S. Patent No. 5,837,492 (issued Novem-
ber 17, 1998). 
8 
 “Isolated DNA” thus refers not simply to physical 
purification,4 but to a molecule that is chemically 
distinct from the larger DNA molecule of the entire 
chromosome. The Federal Circuit wrote that “isolated 
DNA is not just purified DNA. Purification makes 
pure what was the same material, but was combined, 
or contaminated, with other materials [whereas] . . . 
isolated DNA . . . has also been manipulated chemi-
cally [i.e., cleaved from a larger DNA]. . . .” 689 F.3d 
at 1328. 
 Myriad’s claims to “isolated DNA” fragments of 
the human genome are extremely broad. They include 
any DNA fragment of chromosome 17 that contains at 
least 15 nucleotides of the region containing the 
BRCA1 gene. These fragments range in length from 
 
 4 “Purification” of an isolated DNA molecule from a mixture 
of other isolated DNA molecules has been straightforward since 
the invention in the 1970s of recombinant DNA (“gene cloning”). 
A molecular biologist can create a “library” of DNA molecules by 
(i) attaching genomic DNA fragments en masse to “vector” 
molecules, (ii) transferring the resulting molecules en masse into 
bacteria and (iii) growing the resulting bacteria on Petri plates. 
This process yields millions of separate bacterial colonies, each 
carrying an individual segment of DNA from the human ge-
nome. In this way, the first human recombinant library, pro-
duced in 1978, successfully “purified” all the fragments of the 
human genome from one another. Tom Maniatis et al., The 
Isolation of Structural Genes from Libraries of Eucaryotic DNA, 
15 Cell 687 (1978); Richard M. Lawn et al., The Isolation and 
Characterization of Linked Delta- and Beta-globin Genes from a 
Cloned Library of Human DNA, 15 Cell 1557 (1978). Since then 
the challenge has thus not been purifying the fragments, but 
discovering their function. 
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15 nucleotides to nearly the whole chromosome.5 In 
total, the claims cover more than one quadrillion 
distinct fragments from chromosome 17. See Fig. 1.  
 
Figure 1: Examples of the many fragments of “isolated 
DNA” claimed by Myriad’s patent on BRCA1. The frag-
ments range in length from 15 nucleotides to many 
millions of nucleotides, and include any fragment that 
contains 15 nucleotides of the BRCA1 gene region. 
  
 
 5 The concurrence below vastly understated the breadth of 
Myriad’s claim 5. See 689 F.3d at 1341 (“I begin with the short 
isolated sequences such as those covered by claim 5 which is 
directed to ‘an isolated DNA having at least 15 nucleotides of the 
DNA of claim 1.’ This claim covers a sequence as short as 15 
nucleotides and arguably as long as the entire gene.” (emphasis 
added)). An isolated DNA fragment containing virtually all of 
chromosome 17 qualifies as “an isolated DNA having at least 15 
nucleotides of the DNA of claim 1.” 
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B. The Federal Circuit assumed, without 
citing scientific evidence, that isolated 
DNA fragments of the human genome 
do not occur in Nature and therefore 
inappropriately used reasoning-by-
analogy to decide whether such frag-
ments are “similar” to or “markedly 
different” from products of Nature. 
 The central issue in the Federal Circuit’s decision 
was (1) whether DNA fragments from a human 
chromosome are products of Nature or (2) if they are 
not products of Nature, whether they are similar 
enough to products of Nature that they cannot be 
considered “markedly different.” Chakrabarty, 447 
U.S. at 310. 
 The judges agreed that the DNA of a whole 
human chromosome was the patent-ineligible handi-
work of Nature,6 but they disagreed as to the status of 
an isolated DNA fragment of a human chromosome.7  
 The Federal Circuit began its analysis with a 
foundational assumption that the isolated DNA 
fragments claimed by Myriad (such as those shown in 
Figure 1) do not themselves occur in Nature:  
  
 
 6 See 689 F.3d at 1328, 1343 n.6, 1350. 
 7 See 689 F.3d at 1325-33, 1340-43, 1350-58. 
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The isolated DNA molecules before us are 
not found in nature. . . . In this case, the 
claimed isolated DNA molecules do not exist 
in nature within a physical mixture to be pu-
rified. They have to be chemically cleaved 
from their native chemical combination with 
other genetic materials. In other words, in 
nature, the claimed isolated DNAs are cova-
lently bonded to such other materials. Thus, 
when cleaved, an isolated DNA molecule is 
not a purified form of a natural material, but 
a distinct chemical entity that is obtained by 
human intervention. 
689 F.3d at 1325, 1329 (emphasis added). 
 The Federal Circuit cited no scientific support for 
its assertion that the claimed isolated DNA fragments 
do not occur in Nature.  
 Proceeding from this assertion, the Federal 
Circuit then sought to determine whether such iso-
lated DNA fragments are fundamentally similar to 
products of Nature or are markedly “different from 
the natural products in ‘name, character, and use.’ ” 
Id. at 1329 (quoting Chakrabarty, 447 U.S. at 309-
10). The panel members debated whether cleaving a 
DNA fragment from a chromosome was akin to pluck-
ing a leaf from a tree, or surgically removing a kidney 
from a human body. Id. at 1332, 1347, 1352-53. 
Further, the panel members disagreed internally 
regarding whether the breaking of chemical covalent 
bonds rendered the fragments “materially different” 
from naturally occurring DNA. Compare id. at 1329-30 
12 
with id. at 1341 (Moore, J., conc.) and id. at 1350 
(Bryson, J., conc. in part and diss. in part). 
 As shown in the next section, the Federal Circuit 
had no need to engage in this reasoning-by-analogy 
because the foundational assertion that the DNA 
fragments themselves do not occur in Nature is 
demonstrably incorrect.  
 
C. It is well-accepted in the scientific 
community that isolated DNA frag-
ments of the human genome – includ-
ing many fragments covered by 
Myriad’s patents – occur routinely in 
the human body and thus are products 
of Nature. 
 It has been well established for over 30 years 
that isolated DNA fragments of human chromosomes 
routinely occur in the human body. Moreover, these 
isolated DNA fragments span the entire human 
genome, including the BRCA1 and BRCA2 genes. 
Some of the abundant scientific evidence is summa-
rized below. 
 Cell death occurs routinely in the human body, 
with many billions of cells dying every day.8 When 
cells die, chromosomal DNA is broken into fragments 
 
 8 Andrew G. Renehan et al., What is Apoptosis, and Why Is 
It Important?, 322 Br. Med. J. 1536 (2001). 
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as part of a carefully orchestrated natural process.9 
Nature provides the cell with specialized DNA-
cleaving enzymes (called endonucleases); during cell 
death and other critical cellular processes, these 
enzymes have the specific function of breaking cova-
lent bonds that otherwise hold together the DNA 
chain.10  
 The proper control of this natural process is so 
important that mutations that disrupt DNA-cleaving 
enzymes are associated with disease. For example, 
mutations that reduce the activity of a particular 
DNA-cleaving enzyme (called DNAse I) have been 
linked to the auto-immune disease lupus.11 In another 
example, patients who lack either of two other genes 
encoding DNA-cleaving enzymes (involved in repair-
ing DNA damage from ultraviolet light) have a seri-
ous disease called xeroderma pigmentosum, which 
often causes skin cancer.12 
 
 9 Jerry R. Williams et al., Association of Mammalian Cell 
Death with a Specific Endonucleolytic Degradation of DNA, 252 
Nature 754 (1974). 
 10 Xuesong Liu et al., The 40-kDa Subunit of DNA Fragmen-
tation Factor Induces DNA Fragmentation and Chromatin 
Condensation During Apoptosis, 95 Proc. Natl. Acad. Sci. 8461 
(1998). 
 11 Hyoung Doo Shin et al., Common DNase I Polymorphism 
Associated with Autoantibody Production Among Systemic 
Lupus Erythematosus Patients, 13 Hum. Mol. Genet. 2343 
(2004). 
 12 Anneke M. Sijbers et al., Xeroderma Pigmentosum Group 
F Caused by a Defect in a Structure-Specific DNA Repair 
(Continued on following page) 
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 Isolated DNA fragments are not only present in 
cells, but also routinely found in cell-free blood. The 
quantity of freely circulating DNA fragments is 
especially high in the blood of many cancer patients.13 
Such fragments have also been found in substantial 
quantities in the blood of patients with viral infec-
tions,14 exercise overtraining,15 trauma,16 and stroke,17 
and during pregnancy.18 
 The presence of freely circulating isolated DNA 
fragments in the blood is common enough that it can 
 
Endonuclease, 86 Cell 811 (1996); Thierry Nouspikel et al., 
Mutations That Disable the DNA Repair Gene XPG in 
a Xeroderma Pigmentosum Group G Patient, 3 Hum. Mol. Genet. 
963 (1994). 
 13 Maurice Stroun et al., Isolation and Characterization of 
DNA from the Plasma of Cancer Patients, 23 Eur. J. Cancer. 
Clin. Onc. 707 (1987). 
 14 Tran Thi Ngoc Ha et al., Elevated Levels of Cell-Free 
Circulating DNA in Patients with Acute Dengue Virus Infection, 
6 PLoS1 e25969 (2011). 
 15 Ioannis Fatouros et al., Cell-Free Plasma DNA as a Novel 
Marker of Aseptic Inflammation Severity Related to Exercise 
Overtraining, 52 Clin. Chem. 1820 (2006). 
 16 Nicole Y.L. Lam et al., Time Course of Early and Late 
Changes in Plasma DNA in Trauma Patients, 49 Clin. Chem. 
1286 (2003). 
 17 Timothy H. Rainer et al., Prognostic Use of Circulating 
Plasma Nucleic Acid Concentrations in Patients with Acute 
Stroke, 49 Clin. Chem. 562 (2003). 
 18 H. Christina Fan et al., Analysis of the Size Distributions 
of Fetal and Maternal Cell-Free DNA by Paired-End Sequencing, 
56 Clin. Chem. 1279 (2010). 
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be used for identifying genomic mutations in diseases 
such as cancer and cystic fibrosis.19  
 Studies of isolated DNA fragments in human 
blood have found that the fragments have a wide 
range of sizes. Fragments ranging from more than 
80,000 bases to fewer than 100 bases are commonly 
seen.20  
 In pregnancy, both maternal and fetal DNA are 
found in the blood of the mother, with fragments 
smaller than 150 bases observed.21 The presence of 
isolated fragments of fetal DNA in maternal blood 
has resulted in the ability to diagnose fetuses for 
chromosomal disorders (such as Down Syndrome) 
through sequencing of fetal DNA in maternal blood.22  
 
 19 George D. Sorenson et al., Soluble Normal and Mutated 
DNA Sequences from Single-copy Genes in Human Blood, 3 
Cancer Epidemiol. Biomarkers Prev. 67 (1994). 
 20 Mary Beth Giacona et al., Cell-Free DNA in Human 
Blood Plasma: Length Measurements in Patients with Pancreatic 
Cancer and Healthy Controls, 17 Pancreas 89 (1998); Florent 
Mouliere et al., High Fragmentation Characterizes Tumour-
Derived Circulating DNA, 6 PLoS1 e23418 (2011). 
 21 H. Christina Fan et al., Analysis of the Size Distributions 
of Fetal and Maternal Cell-Free DNA by Paired-End Sequencing, 
56 Clin. Chem. 1279 (2010). 
 22 H. Christina Fan et al., Noninvasive Diagnosis of Fetal 
Aneuploidy by Shotgun Sequencing DNA from Maternal Blood, 
105 Proc. Natl. Acad. Sci. 16266 (2008). 
16 
 Multiple studies23 in leading journals have shown 
that the isolated DNA fragments in blood are so 
prevalent and cover the human genome so completely 
that it is “possible to unambiguously determine the 
whole genome sequence of a fetus from a teaspoon’s 
worth of maternal blood.”24  
 Inspection of the publicly available DNA se-
quence data from two of these studies confirms that 
(as expected) the isolated fragments of fetal DNA in 
maternal blood cover the BRCA1 and BRCA2 genes – 
and therefore include many of the isolated DNA 
fragments covered by Myriad’s patents.25  
 Finally, the presence of isolated DNA fragments 
of human chromosomes is not limited to intact cells 
 
 23 H. Christina Fan et al., Non-invasive Prenatal Measure-
ment of the Fetal Genome, 487 Nature 320 (2012); Jacob O. 
Kitzman et al., Noninvasive Whole-Genome Sequencing of a 
Human Fetus, 4 Sci. Transl. Med. 137ra76 (2012); Y.M. Dennis 
Lo et al., Maternal Plasma DNA Sequencing Reveals the Ge-
nome-Wide Genetics and Mutational Profile of the Fetus, 2 Sci. 
Transl. Med. 61ra91 (2010).  
 24 Diana W. Bianchi et al., Fetal Genes in Mother’s Blood, 
487 Nature 304 (2012). 
 25 BRCA1 and BRCA2 data from H. Christina Fan et al., 
Non-invasive Prenatal Measurement of the Fetal Genome, 487 
Nature 320 (2012), are available at http://www.stanford.edu/ 
~quake/brca. Data for Kitzman et al., Noninvasive Whole-
Genome Sequencing of a Human Fetus, 4 Sci. Transl. Med. 
137ra76 (2012), are available at the Genotypes and Phenotypes 
(dbGaP) database of the National Center for Biotechnology 
Information at the National Institutes of Health (http:// 
www.ncbi.nlm.nih.gov/sites/entrez?db=gap, accession number 
phs000500.v1.p1). 
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and cell-free blood. DNA fragments are so pervasive 
as to be found in urine,26 sputum27 and stool.28 Much 
research effort, both in the public and private sector, 
is underway to take advantage of the availability of 
these cell-free DNA fragments for diagnostic testing.29 
 In sum, it is well-accepted in the scientific com-
munity that (a) chromosomes are constantly being 
broken into DNA fragments by natural biological 
processes that break the covalent bonds within DNA 
chains; (b) these DNA fragments can be routinely 
found in the human body, within cells (both living and 
dying) as well as in cell-free blood, urine, sputum and 
stool; and (c) these fragments cover the entire human 
genome and, in particular, include many of the DNA 
fragments claimed by Myriad’s patents. 
 The Federal Circuit thus erred with respect to 
the central issue in its analysis: isolated DNA 
 
 26 Ying-Hsiu Su et al., Human Urine Contains Small, 150 to 
250 Nucleotide-sized, Soluble DNA Derived from the Circulation 
and May Be Useful in the Detection of Colorectal Cancer, 6 J. 
Mol. Diagn. 101 (2004). 
 27 F. B. J. M. Thunnissen et al., Sputum Examination for 
Early Detection of Lung Cancer, 56 J. Clin. Pathol. 805 (2003); 
Miep A. van der Drift, Circulating DNA Is a Non-invasive 
Prognostic Factor for Survival in Non-small Cell Lung Cancer, 
68 Lung Cancer 283 (2008). 
 28 Kevin A. Boynton et al., DNA Integrity as a Potential 
Marker for Stool-based Detection of Colorectal Cancer, 49 Clin. 
Chem. 1058 (2003). 
 29 Annemarie Ziegler et al., Circulating DNA: A New 
Diagnostic Gold Mine?, 28 Cancer Treatment Rev. 255 (2002). 
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fragments from the human genome, including those 
essential for determining a woman’s risk of early-
onset breast cancer and claimed in Myriad’s patents, 
are products of Nature, not the handiwork of humans.  
 
II. MYRIAD’S COMPOSITION-OF-MATTER 
CLAIMS ON ISOLATED FRAGMENTS OF 
GENOMIC DNA ARE INCONSISTENT 
WITH THIS COURT’S SECTION 101  
JURISPRUDENCE BECAUSE THEY (1) 
ARE DIRECTED TO PRE-EXISTING 
PRODUCTS OF NATURE; (2) EXCLUDE 
OTHERS FROM OBSERVING, CHARAC-
TERIZING OR ANALYZING THESE 
PRODUCTS OF NATURE BY ANY MEANS 
WHATSOEVER; AND (3) CREATE AN  
INSURMOUNTABLE BARRIER TO SCI-
ENTIFIC PROGRESS AND TECHNOLOG-
ICAL INNOVATION CONCERNING 
THESE PRODUCTS OF NATURE. 
A. Composition-of-matter claims on 
products of Nature, such as Myriad’s 
claims on naturally occurring DNA 
fragments of the human genome, are 
inconsistent with this Court’s Section 
101 Jurisprudence. 
 Section 101 of the Patent Act defines patentable 
subject matter:  
Whoever invents or discovers any new and 
useful process, machine, manufacture, or 
composition of matter, or any new and useful 
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improvement thereof, may obtain a patent 
therefor, subject to the conditions and re-
quirements of this title. 
35 U.S.C. § 101. 
 “The Court has long held that this provision 
contains an important implicit exception.” Mayo 
Collaborative Servs. v. Prometheus Labs, 132 S. Ct. 
1289, 1293 (2012). “Excluded from such patent pro-
tection are laws of nature, natural phenomena, and 
abstract ideas.” Diamond v. Diehr, 450 U.S. 175, 185 
(1981). The Court has written that “a new mineral 
discovered in the earth or a new plant found in the 
wild is not patentable subject matter. . . . Such dis-
coveries are ‘manifestations of . . . nature, free to all 
men and reserved exclusively to none.’ ” Chakrabarty, 
447 U.S. at 309 (quoting Funk Bros., 333 U.S. at 130). 
 In Chakrabarty, the Court applied this rule to 
a human-made, genetically engineered bacterium 
carrying additional pieces of DNA: 
Judged in this light, respondent’s micro-
organism plainly qualifies as patentable sub-
ject matter. His claim is not to a hitherto  
unknown natural phenomenon, but to a non-
naturally occurring manufacture or composi-
tion of matter – a product of human 
ingenuity “having a distinctive name, char-
acter [and] use.”  
Chakrabarty, 447 U.S. at 309-10 (quoting Hartranft v. 
Wiegmann, 121 U.S. 609, 615 (1887)). 
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 Under Chakrabarty and Mayo, is a DNA mole-
cule related to the human genome patent-eligible? 
The answer depends on the nature of the DNA mole-
cule. It is instructive to compare patent claims for 
three types of DNA molecule: 
 (i) recombinant DNA including human 
genes – for example, a novel DNA molecule, 
in which a human gene has been joined to 
other DNA containing regulatory sequences 
to control its expression and enable produc-
tion of therapeutic protein in a factory. (Most 
economically valuable patents in the bio-
technology industry are of this type.) 
 (ii) human cDNA – that is, a DNA mole-
cule that is obtained by taking a “spliced” 
messenger RNA from a human cell and using 
an enzyme to “reverse transcribe” it from 
RNA to DNA. (These DNA sequences encode 
human proteins and are often used for pro-
ducing proteins in factories.) 
 (iii) human genomic DNA – that is, a 
DNA molecule whose sequence is identical to 
a portion of the human genome. (Myriad’s 
claim to a monopoly on diagnostics involving 
the BRCA1 gene rests on claims to genomic 
DNA.) 
 In the first case, the claim is clearly to “a 
nonnaturally occurring manufacture or composition 
of matter – a product of human ingenuity.” 
Chakrabarty, 447 U.S. at 309. An invention involving 
a human gene in this manner is clearly patent-
eligible. 
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 In the second case, the question is closer but the 
answer is still clear. A cDNA molecule is closely 
related to the RNA from which it has been reverse 
transcribed: in particular, it has the same “infor-
mation content.” But it is produced by a transforma-
tive step30 and is a distinct chemical entity that 
differs from both (i) the RNA (which is a different 
type of nucleic acid) and (ii) the genomic DNA from 
which the RNA was transcribed (which contains 
“intervening sequences”). For this reason, the Federal 
Circuit concluded, unanimously and correctly, that 
cDNA is patent-eligible.31  
 In the third case (the one relevant to Myriad’s 
diagnostic monopoly at hand), the arguments for 
patent-eligibility under Section 101 evaporate. No 
transformative step is involved because, as shown 
above, isolated DNA fragments of the human genome 
occur routinely in Nature. 
 Claims, such as Myriad’s, to isolated DNA frag-
ments of the human genome thus are not directed to 
“a nonnaturally occurring manufacture or composi-
tion of matter – a product of human ingenuity,” but 
rather to a product of Nature itself. Chakrabarty, 447 
U.S. at 309. 
 
 30 It can be argued that the transformative step is straight-
forward, but this speaks to obviousness, not patent-eligibility 
under Section 101. 
 31 See 689 F.3d at 1329, 1340-41, 1348. 
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 A discovery about genomic DNA does not involve 
invention of a new composition of matter, but rather 
is more akin to discovery of a law of Nature pertain-
ing to a product of Nature (for example, that a  
pre-existing DNA sequence is associated with a high-
risk of breast cancer). 
 
B. The rationale for barring patents on a 
product of Nature is strongest when a 
patent would wall off an entire do-
main of Nature from study and inno-
vation. 
 A major purpose behind the “important, implicit 
exception” concerning “ ‘[l]aws of Nature, natural 
phenomena, and abstract ideas’ ” is to avoid the 
“danger that the grant of patents . . . inhibit future 
innovation premised upon them.” Mayo, 132 S. Ct. at 
1293 (citation omitted); see id. at 1301; Diehr, 450 
U.S. at 185.  
 The Court has noted that “phenomena of nature, 
though just discovered, . . . are not patentable, as 
they are the basic tools of scientific and technological 
work.” Gottschalk, 409 U.S. at 67. In Mayo, this Court 
expanded upon Gottschalk, reasoning that the “mo-
nopolization of those tools through the grant of a 
patent might tend to impede innovation more than it 
would tend to promote it.” Mayo, 132 S. Ct. at 1293. 
 “The Court has repeatedly emphasized . . . [the] 
concern that patent law not inhibit further discovery 
by improperly tying up the future use of laws of 
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nature.” Id. at 1301. “[T]he underlying functional 
concern here is . . . how much future innovation is 
foreclosed relative to the contribution of the inventor.” 
Id. at 1303. 
 It follows that the rationale against granting 
patents on the handiwork of Nature is strongest 
when a patent would create an insurmountable 
barrier to innovation.  
 Many patents that pertain to products of Nature 
do not create insurmountable barriers to innovation. 
For example, a monopoly on a particular method for 
studying a product of Nature would not preclude (and 
in fact might encourage) invention of an alternative 
method for studying the product of Nature. Similarly, 
a monopoly on a particular use or set of uses for a 
product of Nature – for example, to treat or prevent a 
disease – would not preclude (and in fact might 
encourage) development of alternative non-natural 
molecules that could substitute for (or improve upon) 
the product of Nature.  
 But the situation is different with respect to a 
composition-of-matter patent on a product of Nature 
(such as genomic DNA). Such a patent can be used to 
exclude everyone from observing, characterizing or 
analyzing, by any means whatsoever, the product of 
Nature. The exclusion is not limited to any particular 
method of analysis; it extends to all possible methods 
of analysis.  
 It is inherently impossible to circumvent this 
barrier. One cannot observe, characterize or analyze a 
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product of Nature if one cannot legally possess it. A 
molecule is one of the “basic tools” – indeed, an essen-
tial tool – for studying the molecule itself. Gottschalk, 
409 U.S. at 67. Granting a monopoly on possessing a 
molecule that is a product of Nature authorizes a 
patent holder to wall off an entire domain of Nature 
from observation.  
 Science is the systematic and cumulative study of 
the natural world. It generates fundamental 
knowledge that not only serves human curiosity but 
also is the intellectual fuel for practical applications, 
including patentable invention. For scientific pro-
gress to proceed, scientists must have the ability to 
study the handiwork of Nature.  
 To illustrate the seriousness of this issue, sup-
pose that a monopoly had been granted on the natu-
rally occurring human immunodeficiency virus (HIV), 
responsible for AIDS, or on the nucleic acid molecule 
that is its genome. The patent holder would have 
been legally entitled to use his patent to block anyone 
from observing, characterizing or analyzing the virus 
by any means whatsoever. Scientists would not have 
been able to rapidly learn the secrets of this insidious 
virus; drug developers would not have been able to 
develop life-saving drugs; technologists would not 
have been able to develop effective diagnostics; and 
patients would not have been able to know their HIV 
status. All of this progress (which saved millions of 
lives and led to many patentable inventions) was 
possible only because observation, characterization, 
and analysis of the product of Nature were open to 
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all. To their credit, the discoverers of HIV obtained 
appropriately narrow patents that do not exclude 
others from observing, characterizing and analyzing 
naturally occurring HIV.  
 
C. Myriad’s composition-of-matter claims 
on genomic DNA are directed to pre-
existing products of Nature; exclude 
others from observing, characterizing 
or analyzing these products of Nature 
by any means whatsoever; and create 
an insurmountable barrier to scien-
tific innovation on these products of 
Nature with serious consequences for 
medical progress and technological 
innovation. 
 The isolated DNA fragments of the human ge-
nome claimed by Myriad are products of Nature, as 
shown above by abundant scientific evidence.  
 The composition-of-matter claims to these frag-
ments allow the patent holder to exclude others from 
observing, characterizing or analyzing these products 
of Nature by any means whatsoever.  
 Such claims erect an insurmountable barrier to 
studying these DNA sequences, with serious conse-
quences for innovation in medicine. For example, only 
a subset of BRCA1 mutations predispose to breast 
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cancer, while others are harmless.32 To accurately 
predict a woman’s risk of breast cancer, one must 
learn which mutations actually create a predisposi-
tion to the disease. This requires characterizing the 
BRCA1 gene in many thousands of women. Myriad’s 
monopoly has seriously inhibited the ability of the 
scientific community to gather sufficient quantities of 
data to fully learn these laws of Nature. 
 
III. A NARROWLY CRAFTED DECISION BY 
THIS COURT WOULD NOT UNDERMINE 
THE BIOTECHNOLOGY INDUSTRY AND 
INSTEAD WOULD FOSTER INNOVATION.  
 In the Federal Circuit’s view, a decision that 
isolated DNA fragments are patent-ineligible would 
disrupt long-settled expectations and could wreak 
havoc on the biotechnology industry. See 689 F.3d at 
1333, 1343-48. In fact, the Federal Circuit’s concern is 
unfounded. 
   
 
 32 Francine Durocher et al., Comparison of BRCA1 Poly-
morphisms, Rare Sequence Variants and/or Missense Mutations 
in Unaffected and Breast/Ovarian Cancer Populations, 5 Hum. 
Mol. Genet. 835 (1996); Alison M. Dunning et al., Common 
BRCA1 Variants and Susceptibility to Breast and Ovarian 
Cancer in the General Population, 6 Hum. Mol. Genet. 285 
(1997). 
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A. Most medically and commercially im-
portant biotechnology products de-
pend on patent protection for non-
naturally occurring DNA molecules, 
such as cDNAs and recombinant DNAs, 
rather than on products of Nature 
such as fragments of genomic DNA. 
 The vast majority of the medically and commer-
cially important biotechnology products developed 
over the past quarter century are protected by pa-
tents on isolated DNA molecules that are non-natural 
compositions of matter, such as cDNA and recombi-
nant DNA molecules – for such uses as artificially 
producing therapeutic proteins. Only a small fraction 
of products involve diagnostic claims to naturally 
occurring genomic DNA. 
 The biotechnology industry would not be sub-
stantially affected by a narrowly crafted decision 
holding that (1) fragments of human genomic DNA 
are patent-ineligible where the scientific evidence is 
clear that the claimed molecules themselves are 
routinely found in Nature and where the process for 
purification or synthesis33 of such molecules is routine 
but (2) human cDNAs are patent-eligible, because 
 
 33 If this Court does not wish to address the question of 
whether products of Nature are patent-ineligible under all 
circumstances, it can address the narrower question of whether 
products of Nature may be patented where their purification or 
synthesis is routine. As described supra in note 4, the physical 
purification of isolated DNA fragments has been routine since 
1978.  
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these molecules do not occur in Nature and have 
clearly different functional properties from related 
products of Nature.34  
 
B. The unfettered ability to observe, 
characterize and analyze the human 
genome will foster scientific progress 
and technological innovation. 
 Any concerns about unsettling expectations 
related to a limited number of diagnostic patents on 
human genomic DNA should be balanced against the 
innovation that will flow from unfettered access to 
this product of Nature. 
 Biomedicine stands on the verge of a revolution 
with major implications for human health. A decade 
ago, the scientific community completed the Human 
Genome Project, which revealed the complete genetic 
code of our species.35 Over the past decade, stunning 
technological advances have reduced the cost of 
sequencing a human genome from billions of dollars 
to thousands of dollars – and it may fall in coming 
years to hundreds of dollars.36 (For reference, Myriad 
charges approximately $3000 to sequence roughly 
four one-millionths of the human genome.)  
 
 34 See supra at 21. 
 35 Eric S. Lander et al., Initial Sequencing and Analysis of 
the Human Genome, 409 Nature 860 (2001). 
 36 Eric S. Lander, Initial Impact of the Sequencing of the 
Human Genome, 470 Nature 187 (2011). 
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 The ability to read entire human genomes is 
unlocking critical secrets about cancer, diabetes, 
schizophrenia and many other diseases. Such studies 
involve identifying genetic variants associated with 
disease based on comprehensive genome studies of 
thousands of patients. These discoveries are making 
it possible to identify and prioritize targets for drug 
development, select patients for clinical trials and 
provide diagnostic and prognostic information. 
 Granting monopolies on the naturally occurring 
DNA of the human genome would impair the ability 
of patients to benefit from the fruits of this genetic 
revolution, by making it difficult or impossible to 
study the human genome as an integrated whole in 
scientific and medical settings. It would risk fencing 
off into a patchwork of private reserves the vast 
expanse of the human genome – one of the most 
remarkable “manifestations of . . . nature, [that 
should be] free to all men and reserved exclusively to 
none.” Funk Bros., 333 U.S. at 130.  
--------------------------------- i --------------------------------- 
 
CONCLUSION 
 It is well-accepted in the scientific community 
that isolated DNA fragments of the human genome – 
including isolated DNA fragments of the BRCA1 and 
BRCA2 genes – are found routinely in the human 
body and are thus patent-ineligible products of 
Nature. The biotechnology industry would not be 
substantially affected by a narrowly crafted decision 
here holding that (1) fragments of human genomic 
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DNA are patent-ineligible where the claimed mole-
cules themselves are routinely found in Nature and 
where the process for purification or synthesis of such 
molecules is routine and (2) cDNAs are patent-
eligible.  
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